Benzinga | Dec 2, 2020 07:15AM EST

Cara Therapeutics Completes Full Enrollment In KARE Phase 2 Trial Of Oral KORSUVA In Atopic Dermatitis Patients With Moderate-To-Severe Pruritus

STAMFORD, Conn., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced that it has completed full enrollment of its KARE Phase 2 dose-ranging clinical trial of Oral KORSUVA(tm) (difelikefalin tablets) for the treatment of moderate-to-severe pruritus in atopic dermatitis patients. The trial has enrolled 400 patients at multiple clinical sites across the United States (US).